ID   PP2BB_HUMAN             Reviewed;         524 AA.
AC   P16298; P16299; Q5F2F9; Q8N1F0; Q8N3W4;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 2.
DT   18-JUN-2025, entry version 196.
DE   RecName: Full=Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform;
DE            EC=3.1.3.16 {ECO:0000269|PubMed:19154138, ECO:0000269|PubMed:26794871};
DE   AltName: Full=CAM-PRP catalytic subunit;
DE   AltName: Full=Calmodulin-dependent calcineurin A subunit beta isoform;
DE            Short=CNA beta {ECO:0000305|PubMed:26794871};
GN   Name=PPP3CB; Synonyms=CALNA2, CALNB, CNA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=2556704; DOI=10.1073/pnas.86.23.9183;
RA   Guerini D., Klee C.B.;
RT   "Cloning of human calcineurin A: evidence for two isozymes and
RT   identification of a polyproline structural domain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9183-9187(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Teratocarcinoma;
RX   PubMed=1848109; DOI=10.1016/0167-4781(91)90069-x;
RA   McPartlin A.E., Barker H.M., Cohen P.T.W.;
RT   "Identification of a third alternatively spliced cDNA encoding the
RT   catalytic subunit of protein phosphatase 2B beta.";
RL   Biochim. Biophys. Acta 1088:308-310(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 2-ALA--PRO-21.
RX   PubMed=19154138; DOI=10.1021/bi8019355;
RA   Kilka S., Erdmann F., Migdoll A., Fischer G., Weiwad M.;
RT   "The proline-rich N-terminal sequence of calcineurin Abeta determines
RT   substrate binding.";
RL   Biochemistry 48:1900-1910(2009).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=25720963; DOI=10.1038/ncb3114;
RA   Medina D.L., Di Paola S., Peluso I., Armani A., De Stefani D., Venditti R.,
RA   Montefusco S., Scotto-Rosato A., Prezioso C., Forrester A., Settembre C.,
RA   Wang W., Gao Q., Xu H., Sandri M., Rizzuto R., De Matteis M.A.,
RA   Ballabio A.;
RT   "Lysosomal calcium signalling regulates autophagy through calcineurin and
RT   TFEB.";
RL   Nat. Cell Biol. 17:288-299(2015).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH IRGM.
RX   PubMed=32753672; DOI=10.1038/s41556-020-0549-1;
RA   Kumar S., Jain A., Choi S.W., da Silva G.P.D., Allers L., Mudd M.H.,
RA   Peters R.S., Anonsen J.H., Rusten T.E., Lazarou M., Deretic V.;
RT   "Mammalian Atg8 proteins and the autophagy factor IRGM control mTOR and
RT   TFEB at a regulatory node critical for responses to pathogens.";
RL   Nat. Cell Biol. 22:973-985(2020).
RN   [10]
RP   INTERACTION WITH SPATA33.
RX   PubMed=34446558; DOI=10.1073/pnas.2106673118;
RA   Miyata H., Oura S., Morohoshi A., Shimada K., Mashiko D., Oyama Y.,
RA   Kaneda Y., Matsumura T., Abbasi F., Ikawa M.;
RT   "SPATA33 localizes calcineurin to the mitochondria and regulates sperm
RT   motility in mice.";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) IN COMPLEX WITH PPP3R1; IRON AND
RP   ZINC, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH
RP   CALMODULIN, AND MUTAGENESIS OF LEU-352; PRO-353; MET-356; 357-ASP--GLN-524;
RP   TRP-361; PHE-365; 397-SER--GLN-524; 415-MET--GLN-524; ARG-417; VAL-418;
RP   PHE-419; SER-420; VAL-421; LEU-422; ARG-423 AND 451-GLN--GLN-524.
RX   PubMed=26794871; DOI=10.1038/cr.2016.14;
RA   Li S.J., Wang J., Ma L., Lu C., Wang J., Wu J.W., Wang Z.X.;
RT   "Cooperative autoinhibition and multi-level activation mechanisms of
RT   calcineurin.";
RL   Cell Res. 26:336-349(2016).
CC   -!- FUNCTION: Calcium-dependent, calmodulin-stimulated protein phosphatase
CC       which plays an essential role in the transduction of intracellular
CC       Ca(2+)-mediated signals (PubMed:19154138, PubMed:25720963,
CC       PubMed:26794871, PubMed:32753672). Dephosphorylates TFEB in response to
CC       lysosomal Ca(2+) release, resulting in TFEB nuclear translocation and
CC       stimulation of lysosomal biogenesis (PubMed:25720963, PubMed:32753672).
CC       Dephosphorylates and activates transcription factor NFATC1
CC       (PubMed:19154138). Dephosphorylates and inactivates transcription
CC       factor ELK1 (PubMed:19154138). Dephosphorylates DARPP32
CC       (PubMed:19154138). Negatively regulates MAP3K14/NIK signaling via
CC       inhibition of nuclear translocation of the transcription factors RELA
CC       and RELB (By similarity). May play a role in skeletal muscle fiber type
CC       specification (By similarity). {ECO:0000250|UniProtKB:P48453,
CC       ECO:0000269|PubMed:19154138, ECO:0000269|PubMed:25720963,
CC       ECO:0000269|PubMed:26794871, ECO:0000269|PubMed:32753672}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83421; EC=3.1.3.16;
CC         Evidence={ECO:0000269|PubMed:19154138, ECO:0000269|PubMed:25720963,
CC         ECO:0000269|PubMed:26794871, ECO:0000269|PubMed:32753672};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:61977; EC=3.1.3.16;
CC         Evidence={ECO:0000269|PubMed:19154138, ECO:0000269|PubMed:26794871};
CC   -!- COFACTOR:
CC       Name=Fe(3+); Xref=ChEBI:CHEBI:29034;
CC         Evidence={ECO:0000269|PubMed:26794871};
CC       Note=Binds 1 Fe(3+) ion per subunit. {ECO:0000269|PubMed:26794871};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:26794871};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:26794871};
CC   -!- ACTIVITY REGULATION: Activated by Ca(2+)-bound calmodulin following an
CC       increase in intracellular Ca(2+) (PubMed:19154138, PubMed:25720963,
CC       PubMed:26794871). At low Ca(2+) concentrations, the catalytic subunit
CC       (also known as calcineurin A) is inactive and is bound to the
CC       regulatory subunit (also known as calcineurin B) in which only two
CC       high-affinity binding sites are occupied by Ca(2+) (PubMed:19154138,
CC       PubMed:26794871). In response to elevated calcium levels, the occupancy
CC       of the low-affinity sites on calcineurin B by Ca(2+) causes a
CC       conformational change of the C-terminal regulatory domain of
CC       calcineurin A, resulting in the exposure of the calmodulin-binding
CC       domain and in the partial activation of calcineurin A (PubMed:19154138,
CC       PubMed:26794871). The subsequent binding of Ca(2+)-bound calmodulin
CC       leads to the displacement of the autoinhibitory domain from the active
CC       site and possibly of the autoinhibitory segment from the substrate
CC       binding site which fully activates calcineurin A (PubMed:19154138,
CC       PubMed:26794871). {ECO:0000269|PubMed:19154138,
CC       ECO:0000269|PubMed:25720963, ECO:0000269|PubMed:26794871}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.69 uM for NFATC1 {ECO:0000269|PubMed:19154138};
CC         KM=0.7 uM for DARPP32 {ECO:0000269|PubMed:19154138};
CC   -!- SUBUNIT: Forms a complex composed of a calmodulin-dependent catalytic
CC       subunit (also known as calcineurin A) and a regulatory Ca(2+)-binding
CC       subunit (also known as calcineurin B) (PubMed:26794871). There are
CC       three catalytic subunits, each encoded by a separate gene (PPP3CA,
CC       PPP3CB, and PPP3CC) and two regulatory subunits which are also encoded
CC       by separate genes (PPP3R1 and PPP3R2) (PubMed:26794871). In response to
CC       an increase in Ca(2+) intracellular levels, forms a complex composed of
CC       PPP3CB/calcineurin A, calcineurin B and calmodulin (PubMed:26794871).
CC       Interacts (via calcineurin B binding domain) with regulatory subunit
CC       PPP3R1/calcineurin B (PubMed:26794871). Interacts (via calmodulin-
CC       binding domain) with calmodulin; the interaction depends on calmodulin
CC       binding to Ca(2+) (PubMed:26794871). Interacts with SLC12A1 (By
CC       similarity). Interacts with SORL1 (By similarity). Interacts with
CC       UNC119 (By similarity). Interacts with MAP3K14/NIK (via C-terminus and
CC       kinase domain) (By similarity). Interacts with TRAF3 (By similarity).
CC       Interacts with SPATA33 (via PQIIIT motif) (PubMed:34446558). Interacts
CC       with IRGM; promoting its association with TFEB and TFEB
CC       dephosphorylation (PubMed:32753672). {ECO:0000250|UniProtKB:P20651,
CC       ECO:0000250|UniProtKB:P48453, ECO:0000269|PubMed:26794871,
CC       ECO:0000269|PubMed:32753672, ECO:0000269|PubMed:34446558}.
CC   -!- INTERACTION:
CC       P16298; P14316: IRF2; NbExp=2; IntAct=EBI-1759540, EBI-2866589;
CC       P16298; P53805: RCAN1; NbExp=3; IntAct=EBI-1759540, EBI-1541887;
CC       P16298; Q99J34: Irak1; Xeno; NbExp=2; IntAct=EBI-1759540, EBI-6117042;
CC       P16298-4; Q96SQ7-1: ATOH8; NbExp=5; IntAct=EBI-26442038, EBI-26429573;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19154138}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=Additional isoforms seem to exist. Calcineurin A beta isoform
CC         consists of at least two isoenzymes that may result from alternative
CC         splicing events.;
CC       Name=1;
CC         IsoId=P16298-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P16298-2; Sequence=VSP_005096, VSP_005097;
CC       Name=3;
CC         IsoId=P16298-3; Sequence=VSP_043803, VSP_012617;
CC       Name=4;
CC         IsoId=P16298-4; Sequence=VSP_043803;
CC   -!- DOMAIN: The poly-Pro domain may confer substrate specificity.
CC       {ECO:0000269|PubMed:19154138}.
CC   -!- DOMAIN: The autoinhibitory domain prevents access to the catalytic
CC       site. {ECO:0000269|PubMed:26794871}.
CC   -!- DOMAIN: The autoinhibitory segment prevents access to the substrate
CC       binding site. {ECO:0000269|PubMed:26794871}.
CC   -!- DOMAIN: Possible isomerization of Pro-318 within the SAPNY motif
CC       triggers a conformation switch which affects the organization and thus
CC       accessibility of the active site and the substrate binding region
CC       (PxIxIF motif). The trans- to cis-transition may favor calcineurin A
CC       activation and substrate binding. The reverse cis- to trans-transition
CC       may be enhanced by peptidyl-prolyl isomerases such as PPIA.
CC       {ECO:0000250|UniProtKB:Q08209}.
CC   -!- MISCELLANEOUS: Unlike for protein substrates, PPP3CB activity towards
CC       synthetic phosphatase substrate p-nitrophenyl phosphate (pNPP) is
CC       increased in presence of the immunosuppressant complex FKBP12-FK506.
CC       {ECO:0000269|PubMed:26794871}.
CC   -!- SIMILARITY: Belongs to the PPP phosphatase family. PP-2B subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M29551; AAA35706.1; -; mRNA.
DR   EMBL; M29550; AAA35705.1; -; mRNA.
DR   EMBL; AJ488506; CAD32694.1; -; mRNA.
DR   EMBL; AL353731; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL359074; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471083; EAW54497.1; -; Genomic_DNA.
DR   EMBL; CH471083; EAW54498.1; -; Genomic_DNA.
DR   EMBL; BC028049; AAH28049.1; -; mRNA.
DR   CCDS; CCDS44436.1; -. [P16298-3]
DR   CCDS; CCDS44437.1; -. [P16298-4]
DR   CCDS; CCDS7328.1; -. [P16298-1]
DR   PIR; A36222; A36222.
DR   PIR; B36222; B36222.
DR   RefSeq; NP_001135825.1; NM_001142353.3. [P16298-4]
DR   RefSeq; NP_001135826.1; NM_001142354.3. [P16298-3]
DR   RefSeq; NP_001276897.1; NM_001289968.2. [P16298-2]
DR   RefSeq; NP_001276898.1; NM_001289969.1.
DR   RefSeq; NP_066955.1; NM_021132.4. [P16298-1]
DR   PDB; 4OR9; X-ray; 2.23 A; A=1-524.
DR   PDB; 4ORA; X-ray; 2.75 A; A=1-524.
DR   PDB; 4ORC; X-ray; 2.70 A; A=1-524.
DR   PDBsum; 4OR9; -.
DR   PDBsum; 4ORA; -.
DR   PDBsum; 4ORC; -.
DR   AlphaFoldDB; P16298; -.
DR   SMR; P16298; -.
DR   BioGRID; 111524; 93.
DR   ComplexPortal; CPX-1002; Calcineurin-Calmodulin complex, beta-R2 variant.
DR   ComplexPortal; CPX-1009; Calcineurin-Calmodulin complex, beta-R1 variant.
DR   ComplexPortal; CPX-1116; Calcineurin-Calmodulin-AKAP5 complex, beta-R2 variant.
DR   ComplexPortal; CPX-998; Calcineurin-Calmodulin-AKAP5 complex, beta-R1 variant.
DR   CORUM; P16298; -.
DR   DIP; DIP-52337N; -.
DR   FunCoup; P16298; 2617.
DR   IntAct; P16298; 58.
DR   MINT; P16298; -.
DR   STRING; 9606.ENSP00000378306; -.
DR   BindingDB; P16298; -.
DR   ChEMBL; CHEMBL5278; -.
DR   DEPOD; PPP3CB; -.
DR   GlyGen; P16298; 1 site, 1 N-linked glycan (1 site).
DR   iPTMnet; P16298; -.
DR   PhosphoSitePlus; P16298; -.
DR   SwissPalm; P16298; -.
DR   BioMuta; PPP3CB; -.
DR   DMDM; 60659599; -.
DR   jPOST; P16298; -.
DR   MassIVE; P16298; -.
DR   PaxDb; 9606-ENSP00000378306; -.
DR   PeptideAtlas; P16298; -.
DR   ProteomicsDB; 53341; -. [P16298-1]
DR   ProteomicsDB; 53342; -. [P16298-2]
DR   ProteomicsDB; 53343; -. [P16298-3]
DR   ProteomicsDB; 53344; -. [P16298-4]
DR   Pumba; P16298; -.
DR   Antibodypedia; 1918; 208 antibodies from 36 providers.
DR   DNASU; 5532; -.
DR   Ensembl; ENST00000360663.10; ENSP00000353881.5; ENSG00000107758.16. [P16298-1]
DR   Ensembl; ENST00000394828.6; ENSP00000378305.2; ENSG00000107758.16. [P16298-3]
DR   Ensembl; ENST00000394829.6; ENSP00000378306.2; ENSG00000107758.16. [P16298-4]
DR   GeneID; 5532; -.
DR   KEGG; hsa:5532; -.
DR   MANE-Select; ENST00000360663.10; ENSP00000353881.5; NM_021132.4; NP_066955.1.
DR   UCSC; uc001jue.4; human. [P16298-1]
DR   AGR; HGNC:9315; -.
DR   CTD; 5532; -.
DR   DisGeNET; 5532; -.
DR   GeneCards; PPP3CB; -.
DR   HGNC; HGNC:9315; PPP3CB.
DR   HPA; ENSG00000107758; Tissue enhanced (skeletal).
DR   MIM; 114106; gene.
DR   OpenTargets; ENSG00000107758; -.
DR   VEuPathDB; HostDB:ENSG00000107758; -.
DR   eggNOG; KOG0375; Eukaryota.
DR   GeneTree; ENSGT00940000154115; -.
DR   InParanoid; P16298; -.
DR   OMA; PSHGLMC; -.
DR   OrthoDB; 5593063at2759; -.
DR   PAN-GO; P16298; 5 GO annotations based on evolutionary models.
DR   PathwayCommons; P16298; -.
DR   Reactome; R-HSA-180024; DARPP-32 events.
DR   Reactome; R-HSA-2025928; Calcineurin activates NFAT.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-5607763; CLEC7A (Dectin-1) induces NFAT activation.
DR   Reactome; R-HSA-9010642; ROBO receptors bind AKAP5.
DR   SignaLink; P16298; -.
DR   SIGNOR; P16298; -.
DR   BioGRID-ORCS; 5532; 69 hits in 1172 CRISPR screens.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; PPP3CB; human.
DR   EvolutionaryTrace; P16298; -.
DR   GeneWiki; PPP3CB; -.
DR   GenomeRNAi; 5532; -.
DR   Pharos; P16298; Tbio.
DR   PRO; PR:P16298; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P16298; protein.
DR   Bgee; ENSG00000107758; Expressed in endothelial cell and 218 other cell types or tissues.
DR   ExpressionAtlas; P16298; baseline and differential.
DR   GO; GO:0005955; C:calcineurin complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0008287; C:protein serine/threonine phosphatase complex; NAS:ComplexPortal.
DR   GO; GO:0030315; C:T-tubule; IEA:Ensembl.
DR   GO; GO:0030018; C:Z disc; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0033192; F:calmodulin-dependent protein phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IDA:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IPI:UniProtKB.
DR   GO; GO:0030346; F:protein phosphatase 2B binding; IDA:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; NAS:UniProtKB.
DR   GO; GO:0048675; P:axon extension; TAS:UniProtKB.
DR   GO; GO:0097720; P:calcineurin-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0033173; P:calcineurin-NFAT signaling cascade; IDA:UniProtKB.
DR   GO; GO:0017156; P:calcium-ion regulated exocytosis; ISS:UniProtKB.
DR   GO; GO:0016311; P:dephosphorylation; TAS:UniProtKB.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0007612; P:learning; TAS:UniProtKB.
DR   GO; GO:0031987; P:locomotion involved in locomotory behavior; IEA:Ensembl.
DR   GO; GO:0001946; P:lymphangiogenesis; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; TAS:UniProtKB.
DR   GO; GO:1905949; P:negative regulation of calcium ion import across plasma membrane; NAS:ComplexPortal.
DR   GO; GO:0023057; P:negative regulation of signaling; ISS:UniProtKB.
DR   GO; GO:0001915; P:negative regulation of T cell mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:0070886; P:positive regulation of calcineurin-NFAT signaling cascade; NAS:ComplexPortal.
DR   GO; GO:1905665; P:positive regulation of calcium ion import across plasma membrane; NAS:ComplexPortal.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; NAS:UniProtKB.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:1905673; P:positive regulation of lysosome organization; IDA:UniProt.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IDA:UniProt.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; ISS:UniProtKB.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; TAS:UniProtKB.
DR   GO; GO:1900242; P:regulation of synaptic vesicle endocytosis; IEA:Ensembl.
DR   GO; GO:0034097; P:response to cytokine; IEA:Ensembl.
DR   GO; GO:0006950; P:response to stress; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   GO; GO:0048741; P:skeletal muscle fiber development; ISS:UniProtKB.
DR   GO; GO:0042110; P:T cell activation; TAS:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; IEA:Ensembl.
DR   GO; GO:0043029; P:T cell homeostasis; IEA:Ensembl.
DR   GO; GO:0001913; P:T cell mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:0042098; P:T cell proliferation; NAS:UniProtKB.
DR   CDD; cd07416; MPP_PP2B; 1.
DR   FunFam; 3.60.21.10:FF:000002; Serine/threonine-protein phosphatase; 1.
DR   Gene3D; 3.60.21.10; -; 1.
DR   InterPro; IPR004843; Calcineurin-like_PHP_ApaH.
DR   InterPro; IPR029052; Metallo-depent_PP-like.
DR   InterPro; IPR041751; MPP_PP2B.
DR   InterPro; IPR043360; PP2B.
DR   InterPro; IPR006186; Ser/Thr-sp_prot-phosphatase.
DR   PANTHER; PTHR45673; SERINE/THREONINE-PROTEIN PHOSPHATASE 2B CATALYTIC SUBUNIT 1-RELATED; 1.
DR   Pfam; PF00149; Metallophos; 1.
DR   PRINTS; PR00114; STPHPHTASE.
DR   SMART; SM00156; PP2Ac; 1.
DR   SUPFAM; SSF101447; Formin homology 2 domain (FH2 domain); 1.
DR   SUPFAM; SSF56300; Metallo-dependent phosphatases; 1.
DR   PROSITE; PS00125; SER_THR_PHOSPHATASE; 1.
DR   neXtProt; NX_P16298; -.
DR   PharmGKB; PA33679; -.
DR   TreeFam; TF105557; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Calmodulin-binding;
KW   Cytoplasm; Hydrolase; Iron; Metal-binding; Phosphoprotein;
KW   Protein phosphatase; Proteomics identification; Reference proteome; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   CHAIN           2..524
FT                   /note="Serine/threonine-protein phosphatase 2B catalytic
FT                   subunit beta isoform"
FT                   /id="PRO_0000058825"
FT   REGION          1..25
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          65..356
FT                   /note="Catalytic"
FT                   /evidence="ECO:0000305"
FT   REGION          357..379
FT                   /note="Calcineurin B binding"
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   REGION          401..415
FT                   /note="Calmodulin-binding"
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   REGION          416..423
FT                   /note="Autoinhibitory segment"
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   REGION          474..496
FT                   /note="Autoinhibitory domain"
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MOTIF           316..320
FT                   /note="SAPNY motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   COMPBIAS        9..22
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        160
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250|UniProtKB:Q08209"
FT   BINDING         99
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000269|PubMed:26794871,
FT                   ECO:0007744|PDB:4OR9, ECO:0007744|PDB:4ORA,
FT                   ECO:0007744|PDB:4ORC"
FT   BINDING         101
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000269|PubMed:26794871,
FT                   ECO:0007744|PDB:4OR9, ECO:0007744|PDB:4ORA,
FT                   ECO:0007744|PDB:4ORC"
FT   BINDING         127
FT                   /ligand="Fe cation"
FT                   /ligand_id="ChEBI:CHEBI:24875"
FT                   /evidence="ECO:0000269|PubMed:26794871,
FT                   ECO:0007744|PDB:4OR9, ECO:0007744|PDB:4ORC"
FT   BINDING         127
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:26794871,
FT                   ECO:0007744|PDB:4OR9, ECO:0007744|PDB:4ORA,
FT                   ECO:0007744|PDB:4ORC"
FT   BINDING         159
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:26794871,
FT                   ECO:0007744|PDB:4OR9, ECO:0007744|PDB:4ORA,
FT                   ECO:0007744|PDB:4ORC"
FT   BINDING         208
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:26794871,
FT                   ECO:0007744|PDB:4OR9, ECO:0007744|PDB:4ORC"
FT   BINDING         290
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:26794871,
FT                   ECO:0007744|PDB:4OR9, ECO:0007744|PDB:4ORA,
FT                   ECO:0007744|PDB:4ORC"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         478
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48453"
FT   VAR_SEQ         137
FT                   /note="E -> EHVLGTEDISINPHNNINE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2556704"
FT                   /id="VSP_005096"
FT   VAR_SEQ         395
FT                   /note="D -> DV (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:1848109"
FT                   /id="VSP_043803"
FT   VAR_SEQ         456..524
FT                   /note="ATVEAIEAEKAIRGFSPPHRICSFEEAKGLDRINERMPPRKDAVQQDGFNSL
FT                   NTAHATENHGTGNHTAQ -> GNDVMQLAVPQMDWGTPHSFANNSHNACREFLLFFSSC
FT                   LSS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2556704"
FT                   /id="VSP_005097"
FT   VAR_SEQ         456..465
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1848109"
FT                   /id="VSP_012617"
FT   MUTAGEN         2..21
FT                   /note="Missing: Increases catalytic efficiency towards
FT                   NFATC1 and DARPP32 but not towards a peptide substrate.
FT                   Does not affect cytoplasmic localization and activation by
FT                   calmodulin."
FT                   /evidence="ECO:0000269|PubMed:19154138"
FT   MUTAGEN         352
FT                   /note="L->A: Severe loss of calmodulin-mediated activation.
FT                   Probably prevents recognition of substrates."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         353
FT                   /note="P->A: Reduction of basal catalytic activity in
FT                   absence of calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         356
FT                   /note="M->A: Modest increase in catalytic activity in
FT                   absence of calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         357..524
FT                   /note="Missing: Loss of catalytic activity. Loss of
FT                   interaction with PPP3R1/calreticulin B and calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         361
FT                   /note="W->A: Severe reduction of basal catalytic activity
FT                   in absence of calmodulin. Severe loss of
FT                   calmodulin-mediated activation. Probably prevents
FT                   recognition of substrates."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         365
FT                   /note="F->A: Moderate loss of calmodulin-mediated
FT                   activation. Probably prevents recognition of substrates."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         398..524
FT                   /note="Missing: Increases catalytic activity independently
FT                   of calmodulin. Loss of interaction with calmodulin. Does
FT                   not affect interaction with PPP3R1/calreticulin B."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         415..524
FT                   /note="Missing: Increases catalytic activity independently
FT                   of calmodulin. Does not affect interaction with
FT                   PPP3R1/calreticulin B and calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         417
FT                   /note="R->A: Modest increase in catalytic activity in
FT                   absence of calmodulin. Does not affect interaction with
FT                   calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         418
FT                   /note="V->A: Does not affect catalytic activity in absence
FT                   of calmodulin. Does not affect interaction with
FT                   calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         419
FT                   /note="F->A: Modest increase in catalytic activity in
FT                   absence of calmodulin. Does not affect interaction with
FT                   calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         420
FT                   /note="S->A: Does not affect catalytic activity in absence
FT                   of calmodulin. Does not affect interaction with
FT                   calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         421
FT                   /note="V->A: Modest increase in catalytic activity in
FT                   absence of calmodulin. Does not affect interaction with
FT                   calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         422
FT                   /note="L->A: Modest increase in catalytic activity in
FT                   absence of calmodulin. Does not affect interaction with
FT                   calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         423
FT                   /note="R->A: Modest increase in catalytic activity in
FT                   absence of calmodulin. Does not affect interaction with
FT                   calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   MUTAGEN         451..524
FT                   /note="Missing: Increases basal catalytic activity. Does
FT                   not affect interaction with PPP3R1/calreticulin B and
FT                   calmodulin."
FT                   /evidence="ECO:0000269|PubMed:26794871"
FT   HELIX           21..23
FT                   /evidence="ECO:0007829|PDB:4ORA"
FT   HELIX           40..43
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           52..60
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           67..82
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          86..90
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          92..97
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           104..114
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   TURN            117..119
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          122..124
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          129..132
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           135..148
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   TURN            150..152
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          153..155
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           163..168
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           171..178
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           181..192
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          196..200
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   TURN            201..203
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          204..209
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           218..222
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          232..234
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           235..241
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   TURN            246..249
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          256..259
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   TURN            261..263
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          264..269
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           271..281
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          284..288
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          296..299
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   TURN            304..306
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          308..315
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           320..322
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          328..334
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          337..343
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           353..355
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           358..378
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   STRAND          381..383
FT                   /evidence="ECO:0007829|PDB:4ORA"
FT   TURN            384..386
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           479..485
FT                   /evidence="ECO:0007829|PDB:4OR9"
FT   HELIX           488..490
FT                   /evidence="ECO:0007829|PDB:4OR9"
SQ   SEQUENCE   524 AA;  59024 MW;  7661183F3C2362C8 CRC64;
     MAAPEPARAA PPPPPPPPPP PGADRVVKAV PFPPTHRLTS EEVFDLDGIP RVDVLKNHLV
     KEGRVDEEIA LRIINEGAAI LRREKTMIEV EAPITVCGDI HGQFFDLMKL FEVGGSPANT
     RYLFLGDYVD RGYFSIECVL YLWVLKILYP STLFLLRGNH ECRHLTEYFT FKQECKIKYS
     ERVYEACMEA FDSLPLAALL NQQFLCVHGG LSPEIHTLDD IRRLDRFKEP PAFGPMCDLL
     WSDPSEDFGN EKSQEHFSHN TVRGCSYFYN YPAVCEFLQN NNLLSIIRAH EAQDAGYRMY
     RKSQTTGFPS LITIFSAPNY LDVYNNKAAV LKYENNVMNI RQFNCSPHPY WLPNFMDVFT
     WSLPFVGEKV TEMLVNVLSI CSDDELMTEG EDQFDGSAAA RKEIIRNKIR AIGKMARVFS
     VLREESESVL TLKGLTPTGM LPSGVLAGGR QTLQSATVEA IEAEKAIRGF SPPHRICSFE
     EAKGLDRINE RMPPRKDAVQ QDGFNSLNTA HATENHGTGN HTAQ
//
